

Durysta® (bimatoprost intracameral implant)

When requesting Durysta® (bimatoprost intracameral implant), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Durysta (bimatoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Coverage Guidelines

Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

The individual must meet all of the following criteria for authorization:

- Is 18 years of age or older;
- Is not receiving re-treatment of eye(s) previously treated with Durysta;
- Has experienced inadequate efficacy or severe adverse events to at least two ophthalmic prostaglandins (as monotherapy or concomitant therapy) for the treatment of open-angle glaucoma or ocular hypertension (e.g., bimatoprost ophthalmic solution, latanoprost ophthalmic solution, travoprost ophthalmic solution; latanoprostene bunod ophthalmic solution, tafluprost ophthalmic solution, and omidenepag isopropyl ophthalmic solution);
- Has experienced inadequate efficacy or severe adverse events to at least two ophthalmic products (as monotherapy or concomitant therapy) from two different pharmacologic classes for the treatment of open-angle glaucoma or ocular hypertension (e.g., beta-blockers, alpha-agonist [brimonidine], carbonic anhydrase inhibitors, and rho kinase inhibitor [netarsudil]);
- Durysta is administered by or under the supervision of an ophthalmologist.

Approval duration: one implant per treated (eyes)

Dosing Recommendation

Durysta is an ophthalmic drug delivery system for a single intracameral administration of a biodegradable implant. Durysta should not be readministered to an eye that received a prior Durysta.

The recommended dose is one Durysta implant per treated eye(s), a total of two implants per patient.

References

1. Durysta™ [prescribing information]. Madison, NJ: Allergan USA, Inc; October 2024.
2. Goyal A. Understanding glaucoma: symptoms, causes, diagnosis, treatment. Available at: <https://www.aao.org/eye-health/diseases/what-is-glaucoma>. Published January 5, 2026. Accessed on February 19, 2026.
3. Gedde SJ, Vinod K, Wright MW, et al. The American Academy of Ophthalmology. Primary Open-Angle Glaucoma Preferred Practice Pattern.® 2020 Available at: [https://www.aaojournal.org/article/S0161-6420\(20\)31024-1/fulltext](https://www.aaojournal.org/article/S0161-6420(20)31024-1/fulltext). Accessed on February 19, 2026.
4. iDose® TR intracameral implant [prescribing information]. San Clemente, CA: Glaukos; January 2026.